UPDATE: Citi Downgrades Gilead Sciences (GILD) to Neutral

(updated to add analyst comment)

Citi analyst Robyn Karnauskas downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Neutral with a price target of $75.00 (from $100.00).

The analyst steps to the sidelines after admitting error on an expectation for NASH to work. She says without NASH the company will now need to rely on M&A to grow.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $67.62 yesterday.

You May Also Be Interested In

• Snowflake Inc. (SNOW) PT Raised to $450 at Freedom Broker
• StoneX Starts PulteGroup (PHM) at Buy
• Asana (ASAN) PT Raised to $10 at UBS, Neutral Rating Maintained on 'Full' Valuation